Skip to main content
. 2020 Oct 29;10:569584. doi: 10.3389/fonc.2020.569584

Figure 1.

Figure 1

The expression characteristics of LOXL2 in the public database. LOXL2 levels were checked in different grades (A), subtypes (D), and isocitrate dehydrogenase (IDH) mutation statuses (G) in The Cancer Genome Atlas (TCGA) cohort. LOXL2 expression levels assessed in different grades (B), subtypes (E), and IDH mutation statuses (H) in the Chinese Glioma Genome Atlas (CGGA) cohort. LOXL2 expression levels assessed in different grades (C), subtypes (F), and IDH mutation statuses (I) in the GSE16011 cohort. Kaplan-Meier ananlysis examined the relationship between LOXL2 and overall survival of patients with all gliomas (J), LGG (K), and GBM (L) in TCGA. *P < 0.05; **P < 0.01; ***P < 0.005.